Combined MAPK and NAMPT Inhibition: Greater Efficacy in Axonal Degeneration

Value Proposition

• Demonstrates synergistic effect of targeting two biochemical pathways.
• Offers possible disease-modifying therapy for degenerative diseases of the axons.
• Possible treatment to minimize damage from acute brain injury.

Unmet Need

Degeneration of axons is a hallmark feature of various neurological conditions. Deterioration of axons is observed after traumatic brain injury (TBI), glaucoma, multiple different peripheral neuropathies, and in neurodegenerative diseases. Many of these conditions are age-related, and thus the prevalence of these diseases is predicted to rise as people live longer lives (Checkoway et al. 2011).

No disease-altering treatments exist for neurodegenerative conditions. Current treatments primarily address symptomatic management and supportive care for patients. While various labs and private companies are investigating definitive treatments, no long-term solution has yet reached the market. Direct action against axonal degeneration would be a revolutionary opportunity in the realm of neurological disease.

Technology Description

Researchers at Johns Hopkins have developed a technology that allows for inhibition of axonal degeneration. The method involves the use of small molecules to target two different biochemical pathways implicated in neurodegeneration.

Stage of Development

• In vitro studies have been completed, demonstrating axon protection using MAPK inhibition, NAMPT inhibition, and synergistic combined inhibition. In vivo studies are underway.
• Data available upon request.

Publication

• US Patent Application US20220218662A1
• Alexandris, Athanasios S., and Vassilis E. Koliatsos. "NAD+, Axonal Maintenance, and Neurological Disease." Antioxidants & Redox Signaling” (2023).